Semaglutide copies arrive as key patents lapse outside the US and Europe
With patent protection ending in markets such as India and Canada, manufacturers lined up their own semaglutide. Making a 31-amino-acid peptide at scale is not the same as copying a pill.
What's new
Drugmakers announced semaglutide launches after core patent protection ended in India, with other markets including Canada, China and Brazil on similar timelines.
Why it matters
Prices for the same peptide may soon differ several-fold depending on the country.
What's next
Quality inspections, the first price points and whether regulators treat these as generics or biosimilars.
The core patent on semaglutide does not expire everywhere at once. In 2026 protection ended in several large markets outside the United States and the European Union, and manufacturers that had prepared for years announced their own versions.
Why the timing differs by country
Patents are national. Their length depends on filing dates, local extension rules and, in some cases, whether the holder kept paying maintenance fees. That is why semaglutide can be off-patent in one country and protected for years in another.
Copying a peptide is harder than copying a pill
| Step | Small-molecule generic | Semaglutide copy |
|---|---|---|
| Making the active ingredient | Standard chemical synthesis | Peptide synthesis or recombinant production plus a fatty-acid side chain |
| Proving sameness | Chemical identity, blood levels | Identity plus impurity profile, which affects immune reactions |
| Device | Usually none | Pen injector for weekly doses |
Regulators look closely at impurities because small differences in peptide by-products can change how the immune system reacts.
What to watch
- How quickly prices fall and whether supply is reliable.
- Whether copies are sold under strict prescription rules or leak into grey-market channels.
- Cross-border buying from places where the patent has expired into places where it has not, which remains illegal in protected markets.
